401 Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Moyamoya Disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease that is commonly associated with comorbidities like type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (GLP-1) receptor agonists are antihyperglycemic agents that have demonstrated the ability to reduce stroke. METHODS: T2DM patients with MMD were retrospectively identified from the TriNetX Research Network. Propensity-score matching was used to create two cohorts based on history of GLP-1 receptor agonist prescription. Kaplan Meier survival curves were used to analyze outcomes of interest- stroke, intracerebral hemorrhage (ICH) and mortality. RESULTS: Of 2,898 MMD patients with T2DM, 573 (19.7%) had a history of GLP-1 receptor agonist prescription and 2,325 (80.3%) did not have a history of GLP-1 receptor agonist prescription. PSM resulted in 322 patients in each group. Patients with MMD and T2DM who received GLP-1 receptor agonists had 32% lower risk of stroke (HR: 0.68, 95% CI: 0.55-0.83, P < 0.001), 65% lower risk of ICH (HR: 0.35, 95% CI: 0.17-0.70, P < 0.01) and 68% lower risk of mortality (HR: 0.32, 95% CI: 0.16-0.62, P < 0.001) compared to MMD patients with T2DM who did not receive GLP-1 receptor agonists. CONCLUSIONS: In this study, MMD patients with T2DM prescribed a GLP-1 receptor agonist had lower risk of stroke, ICH and mortality. Prospective studies and RCTs are needed to clarify their role in MMD management.
Fields of Study & Subjects
Moyamoya disease diagnosis and treatment
Diabetes Treatment and Management
Diabetes Management and Research
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 112–112
- Publication date
- 26 March 2026
- Language
- EN